NTRR Partner S2O2 Signs LOI With Leading Cannabis Laboratory to Test Cutting-Edge Horticultural Products

Just days after a letter of intent to test and demonstrate their cutting-edge horticultural products at indoor cannabis cultivation facilities in Colorado was made public, Neutra Corp. (OTCBB:NTRR) and its joint venture partner Surface to Air Solutions, Inc. (S2O2) announced today that the testing procedures will be undertaken by one of the country’s top cannabis laboratories.

The Denver-based laboratory company signed a letter of intent this month with S2O2 to act as a third-party lab collecting weekly surface samples at the cultivation operations where the joint venture’s products are being tested. These surface samples will be tested for microbes, which the joint venture’s suite of products are designed to eliminate. The case study will also include biological and cannabinoid testing of cannabis flowers in order to validate the biological controls.

Neutra Corp. and its joint venture partner expect that the case study will prove conclusively that S2O2’s products can help cannabis cultivators eliminate microbes and other pests and contaminants from growing facilities without the use of harsh chemicals and pesticides.

“This letter of intent is with one of very few companies in the cannabis industry with the expertise to conduct this kind of testing,” said NTRR CEO Chris Brown. “We’re very pleased to be able to work with them on this project, and we’re confident that their results will be viewed as trusted information by the other big players in Colorado’s booming cannabis industry.”

S2O2’s antimicrobial surface treatment, nutritional plant tonic and air-scrubbing hydroxyl generator will be tested at facilities run by DANK Dispensaries and Denver Consulting Group for three months. NTRR formed its joint venture with S2O2 last year to market these and other novel solutions to growers that are concerned about contamination of their crops by microbes, molds, fungus and other pests.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.